Hematology and Lymphoma

As with many areas of medical science, the fields relating to the research and treatment of cancers are full of highly specialized terminology. Some words are used interchangeably—and seemingly arbitrarily—while others are used one way in common practice despite having very different meanings in formal practice. Oncology and hematology are often both used in discussions and literature about lymphoma, but many do not know the difference, or the proper places to use one or the other. Understanding oncology, hematology and lymphoma will make it easier to understand much of the written material on the subject.

Oncology

As a very broad field of medical study, oncology refers to the investigation of distinctive malignancies or cancers. These cancers result from genetic mutation or cellular trauma causing some cells to grow much more quickly than usual, and in a destructive manner.

For the purposes of this article, the distinctive feature of oncology as a field of study is that it treats cancers in any area of the body. These can include cancer of the mouth, throat, brain, breast, prostate, colon, lung, ovaries, or the blood. It is the last area—the blood—that links oncology and hematology, as we shall see.

Hematology

Hematology is the high-level study of the blood and the blood-forming organs, including diseases of the blood. Some of the diseases or sub-specialities studied by hematologists include the following:

  • Bleeding disorders, like hemophilia
  • Hemoglobinopathies
  • Blood transfusions
  • Stem cell or bone marrow transplants
  • Blood-based malignancies (cancers) like leukemia or lymphoma

So, to simply things, oncologists study cancer, which may involve the blood, and hematologists study the blood, which may be the site of cancer. Lymphoma is what happens when these two fields overlap.

Lymphoma

Along with leukemia, lymphoma is a cancer of the blood. Where leukemia attacks white blood cells, lymphoma targets the lymphocytes, elements of the body's lymphatic system. Lymphoma can, therefore, be approached and treated by either a hematologist or an oncologist, or more commonly, both. Often a hematologist will run blood tests to determine whether a cancer diagnosis in called for, at which point an oncologist will prescribe and commence treatment. As treatment progresses, both may need to remain involved in patient monitoring.

Conclusion

Oncology, hematology and lymphoma are all terms that refer to a specific thing, but the meaning of the first two terms may overlap in circumstances dealing with the third term, lymphoma. One doctor may study brain tumors and another clotting disorders. In this case, their areas of study do not overlap, but both could legitimately study lymphoma from two different areas without a conflict in definition.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap